PCI Synthesis Adds Manufacturing, QC, Business, and R&D Expertise
PCI Synthesis, Inc., a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, has significantly increased its bench strength in quality control and research and development with the hiring of several experts in recent months.
New in-house experts include:
- Elie Saikali, Ph.D., Director of Manufacturing: A holder of seven patents and a rich publication history, Elie Saikali oversees and directs all manufacturing operations according to cGMP, FDA and ICH guidelines. Dr. Saikali comes to PCI Synthesis from Lonza Inc. where he held increasingly responsible positions in process research and development ultimately holding the title of product manager. He earned his doctorate at Wake Forest University, and a master’s of science from North Carolina Agricultural and Technical State University.
- Mehdi Yazdi, Ph.D., Director of Quality Control and Analytical Services: With a doctorate from the University of Mississippi, Mehdi Yazdi is focused on improving PCI’s entire Quality Control and Analytical Development function. In his short time at PCI Synthesis, Dr. Yazdi has been instrumental in revamping the entire department, including improving training, ensuring consistency, building an analytical development team that has significantly improved outcomes. He joined the company from Clariant Life Science Molecules, where he was served as QC Manager; prior to that he was with DPT, responsible for the analytical development of both large and small molecule finished dosage forms.
- Don Dickison, Director of Business Development: With a successful career in pharmaceutical sales and sales management, Don Dickison is responsible for the day-to-day business development activities for fine and specialty chemicals including emerging Pharma. His prior experience includes posts at PRS Pharma and almost a decade and a half with Eli Lilly in various sales and sales management roles. Dickison holds a bachelor’s degree from the University of New Brunswick.
- Paul Nichols, Ph.D., Director of cGMP Kilo Lab: In this role, Paul Nichols is responsible for early phase clinical drug substance development and manufacturing for PCI’s’ clients. Dr. Nichols comes to the company after several years at Array BioPharma, where he held the position of Senior Research Investigator. Before that, Dr. Nichols worked at Abbott Labs as a Research Scientist. He earned a doctorate from the University of Colorado at Boulder, a master’s of science from San Diego State University and a bachelor’s degree from the University of California at San Diego.
These new hires are part of PCI Synthesis’ strategic initiative that has included the completion of major expansion of the company’s Devens, Mass Research and Development facility. The expansion, which was completed last month, includes several new research hoods, analytical instruments, additional support equipment, additional staff, and a major expansion to the site's existing kilo lab capacity, was initiated to support PCI’s expanding activities in early- and late-stage clinical candidate programs. Since September 1st, the company has brought on board 20 new staff members in several functional areas to further support its growth in development of new compounds.
All together the additional staff and capacity enables PCI to offer its biotech and pharmaceutical customers a bridge from lab scale development to commercial manufacturing. This represents an important intermediate step as customers work on new compounds for new therapies, conduct clinical trials and seek to bring products to market. The 30-percent capacity increase positions PCI to handle increased customer demand. Part of the expansion was driven by a new collaboration agreement with Biogen Idec to work closely with its process research group to augment its internal small-molecules capabilities and optimize a number of new compounds.
Birnbach Communications, Inc.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.